Inclusion Criteria:

- Histologically proven squamous cell carcinoma of the esophagus(include cardiac
cancer)

- Newly diagnosed patients should be unable or unwilling to surgery

- Recurrence after surgery must have no adjuvant chemotherapy or radiotherapy are
allowed

- Patients are required to have dimensionally measurable disease,with an objective
measurable focus:preferably the use of spiral computed tomography(CT)and measurements
of maximum diameter≥1cm.

- Cooperative Oncology Group performance status 0-2 or KPS score ≥60,survival time ≥3
months

- Neutrophils(ANC)≥1.5×109/L; blood platelets counts(BPC)≥80×109/L

- Hemoglobin(Hgb)≥90g/L ,serum total bilirubin ≤1.0 times the upper normal limit(ULN):
alanine aminotransferase and glutamic-oxalacetic transaminase (ALT and AST)≤2.5 ULN

- Serum creatinine (Cr)≤1.5ULN

Exclusion Criteria:

- pregnant or nursing women;

- Female patients at child-bearing age, without taking effective contraceptive methods;

- patients who have pathologic confirmation of other types of tumors (eg,
leiomyosarcoma, malignant lymphoma) rather than esophageal cancer;

- patients with tumors other than esophageal cancer ,except cervical carcinoma in situ
and skin basal cancer or squamous cell carcinoma received adequate treatment;

- patients with cerebral or meningeal metastasis, intestinal obstruction, or
symptomatic pathologic changes of peripheral nerve,NCIC-CTG standard >grade 2

- patients with serious complications such as: serious heart disease remained unstable
after treatment, or myocardial infarction, congestive heart failure, unstable
angina, frank pericardial effusion or unstable arrhythmias in 6 months before being
enrolled into the group; confirmed neuropathy or psychosis, including dementia or
epilepsia; uncontrolled infection;active disseminated intravascular
coagulation;uncontrolled diabetes, fasting serum glucose> 7.8mmol / L